L. Robin Keller

Decision Sciences · Social Sciences

25h-index2.0kcitations122works0.12yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Decision-Making and Behavioral Economics(47), Economic and Environmental Valuation(32), Forecasting Techniques and Applications(16), Health Systems, Economic Evaluations, Quality of Life(13), Bayesian Modeling and Causal Inference(11)

Publications122 total

One Script Instead of Hundreds? On Pretraining Romanized Encoder Language Models
ArXiv.org·2026Open Access
One Script Instead of Hundreds? On Pretraining Romanized Encoder Language Models
arXiv (Cornell University)·2026Open Access
Modeling cost-effectiveness analysis of treatment sequencing
Socio-Economic Planning Sciences·2025Open Access
SpeechTaxi: On Multilingual Semantic Speech Classification
2025
SpeechTaxi: On Multilingual Semantic Speech Classification
arXiv (Cornell University)·2024Open Access
The Application-Layer Traffic Optimization (ALTO) Transport Information Publication Service (TIPS)
2024
Market Audits Combat Cannabis Misinformation
Journal of Testing and Evaluation·2024
Counterfeits can benefit original products when people are caught using counterfeits
Psychology and Marketing·2024· 1 cited
When Are We Willing to Wait? Prescriptive Challenges in Evaluating Intertemporal Outcomes
International series in management science/operations research/International series in operations research & management science·2024
Tip or No Tip? That is the Question
SSRN Electronic Journal·2023Open Access
Communicating Health Risks to the Public
Przegląd Organizacji·2021Open Access
Interdependent Altruistic Preference Models
Decision Analysis·2020· 12 citedOpen Access
Valuing Sequences of Lives Lost or Saved Over Time: Preference for Uniform Sequences
Decision Analysis·2020· 9 citedOpen Access
Comparing Markov and non-Markov alternatives for cost-effectiveness analysis: Insights from a cervical cancer case
Operations Research for Health Care·2019· 14 cited
Cost-effectiveness of maintenance therapy in advanced ovarian cancer: Paclitaxel, bevacizumab, niraparib, rucaparib, olaparib, and pembrolizumab.
Journal of Clinical Oncology·2018· 6 cited
MARKOV CHAIN MODELS IN PRACTICE: A REVIEW OF LOW COST SOFTWARE OPTIONS
Library Open Repository (Universidad Complutense Madrid)·2018· 2 citedOpen Access
Preference Functions for Spatial Risk Analysis
Risk Analysis·2017· 19 citedOpen Access
Evaluating the cost-effectiveness of current FDA-approved PARP inhibitors for the treatment of recurrent ovarian cancer.
Journal of Clinical Oncology·2017· 7 cited
Counterfeits Can Benefit Original Brands When People Are Caught Using Counterfeits: the Role of Face Restoration
ACR North American Advances·2017· 4 cited
Intention–Behavior Discrepancy of Foreign versus Domestic Brands in Emerging Markets: The Relevance of Consumer Prior Knowledge
Journal of International Marketing·2016· 33 cited
page 1 of 7Next →

Frequent Co-authors

Joanna L.Y. Ho(5), Yitong Wang(5), Tianjun Feng(4), Rakesh K. Sarin(4), Liangyan Wang(4), Jay Simon(4), Pamela Keltyka(3), Craig W. Kirkwood(3), Xiaona Zheng(2), Jeffery L. Guyse(2), Jiaru Bai(2), Monika Winn(2), Wen‐Qiang Bian(2), Richard L. Daniels(2), Lauraine G. Chestnut(1), William E. Lambert(1), Robert D. Rowe(1), James M. Leonhardt(1), Cornelia Pechmann(1), Martin Weber(1)